In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation

Dhaya Seshasayee, Wyne P. Lee, Meijuan Zhou, Jean Shu, Eric Suto, Juan Zhang, Laurie Diehl, Cary D. Austin, Y. Gloria Meng, Martha Tan, Sherron L. Bullens, Stefan Seeber, Maria E. Fuentes, Aran F. Labrijn, Yvo M F Graus, Lisa Miller, Edward S Schelegle, Dallas M. Hyde, Lawren C. Wu, Sarah G. Hymowitz & 1 others Flavius Martin

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Thymic stromal lymphopoietin (TSLP) potently induces deregulation of Th2 responses, a hallmark feature of allergic inflammatory diseases such as asthma, atopic dermatitis, and allergic rhinitis. However, direct downstream in vivo mediators in the TSLP-induced atopic immune cascade have not been identified. In our current study, we have shown that OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. Treating mice with OX40L-blocking antibodies substantially inhibited immune responses induced by TSLP in the lung and skin, including Th2 inflammatory cell infiltration, cytokine secretion, and IgE production. OX40L-blocking antibodies also inhibited antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. This treatment resulted in both blockade of the OX40-OX40L receptor-ligand interaction and depletion of OX40L-positive cells. The use of a blocking, OX40L-specific mAb thus presents a promising strategy for the treatment of allergic diseases associated with pathologic Th2 immune responses.

Original languageEnglish (US)
Pages (from-to)3868-3878
Number of pages11
JournalJournal of Clinical Investigation
Volume117
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

OX40 Ligand
Inflammation
Blocking Antibodies
OX40 Receptor
Asthma
Th2 Cells
Atopic Dermatitis
Immunoglobulin E
Primates
thymic stromal lymphopoietin
Cytokines
Ligands
Antigens
Lung
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Seshasayee, D., Lee, W. P., Zhou, M., Shu, J., Suto, E., Zhang, J., ... Martin, F. (2007). In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. Journal of Clinical Investigation, 117(12), 3868-3878. https://doi.org/10.1172/JCI33559

In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. / Seshasayee, Dhaya; Lee, Wyne P.; Zhou, Meijuan; Shu, Jean; Suto, Eric; Zhang, Juan; Diehl, Laurie; Austin, Cary D.; Meng, Y. Gloria; Tan, Martha; Bullens, Sherron L.; Seeber, Stefan; Fuentes, Maria E.; Labrijn, Aran F.; Graus, Yvo M F; Miller, Lisa; Schelegle, Edward S; Hyde, Dallas M.; Wu, Lawren C.; Hymowitz, Sarah G.; Martin, Flavius.

In: Journal of Clinical Investigation, Vol. 117, No. 12, 12.2007, p. 3868-3878.

Research output: Contribution to journalArticle

Seshasayee, D, Lee, WP, Zhou, M, Shu, J, Suto, E, Zhang, J, Diehl, L, Austin, CD, Meng, YG, Tan, M, Bullens, SL, Seeber, S, Fuentes, ME, Labrijn, AF, Graus, YMF, Miller, L, Schelegle, ES, Hyde, DM, Wu, LC, Hymowitz, SG & Martin, F 2007, 'In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation', Journal of Clinical Investigation, vol. 117, no. 12, pp. 3868-3878. https://doi.org/10.1172/JCI33559
Seshasayee, Dhaya ; Lee, Wyne P. ; Zhou, Meijuan ; Shu, Jean ; Suto, Eric ; Zhang, Juan ; Diehl, Laurie ; Austin, Cary D. ; Meng, Y. Gloria ; Tan, Martha ; Bullens, Sherron L. ; Seeber, Stefan ; Fuentes, Maria E. ; Labrijn, Aran F. ; Graus, Yvo M F ; Miller, Lisa ; Schelegle, Edward S ; Hyde, Dallas M. ; Wu, Lawren C. ; Hymowitz, Sarah G. ; Martin, Flavius. / In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 12. pp. 3868-3878.
@article{e93c101bf0b74070b052a954103ef187,
title = "In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation",
abstract = "Thymic stromal lymphopoietin (TSLP) potently induces deregulation of Th2 responses, a hallmark feature of allergic inflammatory diseases such as asthma, atopic dermatitis, and allergic rhinitis. However, direct downstream in vivo mediators in the TSLP-induced atopic immune cascade have not been identified. In our current study, we have shown that OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. Treating mice with OX40L-blocking antibodies substantially inhibited immune responses induced by TSLP in the lung and skin, including Th2 inflammatory cell infiltration, cytokine secretion, and IgE production. OX40L-blocking antibodies also inhibited antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. This treatment resulted in both blockade of the OX40-OX40L receptor-ligand interaction and depletion of OX40L-positive cells. The use of a blocking, OX40L-specific mAb thus presents a promising strategy for the treatment of allergic diseases associated with pathologic Th2 immune responses.",
author = "Dhaya Seshasayee and Lee, {Wyne P.} and Meijuan Zhou and Jean Shu and Eric Suto and Juan Zhang and Laurie Diehl and Austin, {Cary D.} and Meng, {Y. Gloria} and Martha Tan and Bullens, {Sherron L.} and Stefan Seeber and Fuentes, {Maria E.} and Labrijn, {Aran F.} and Graus, {Yvo M F} and Lisa Miller and Schelegle, {Edward S} and Hyde, {Dallas M.} and Wu, {Lawren C.} and Hymowitz, {Sarah G.} and Flavius Martin",
year = "2007",
month = "12",
doi = "10.1172/JCI33559",
language = "English (US)",
volume = "117",
pages = "3868--3878",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation

AU - Seshasayee, Dhaya

AU - Lee, Wyne P.

AU - Zhou, Meijuan

AU - Shu, Jean

AU - Suto, Eric

AU - Zhang, Juan

AU - Diehl, Laurie

AU - Austin, Cary D.

AU - Meng, Y. Gloria

AU - Tan, Martha

AU - Bullens, Sherron L.

AU - Seeber, Stefan

AU - Fuentes, Maria E.

AU - Labrijn, Aran F.

AU - Graus, Yvo M F

AU - Miller, Lisa

AU - Schelegle, Edward S

AU - Hyde, Dallas M.

AU - Wu, Lawren C.

AU - Hymowitz, Sarah G.

AU - Martin, Flavius

PY - 2007/12

Y1 - 2007/12

N2 - Thymic stromal lymphopoietin (TSLP) potently induces deregulation of Th2 responses, a hallmark feature of allergic inflammatory diseases such as asthma, atopic dermatitis, and allergic rhinitis. However, direct downstream in vivo mediators in the TSLP-induced atopic immune cascade have not been identified. In our current study, we have shown that OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. Treating mice with OX40L-blocking antibodies substantially inhibited immune responses induced by TSLP in the lung and skin, including Th2 inflammatory cell infiltration, cytokine secretion, and IgE production. OX40L-blocking antibodies also inhibited antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. This treatment resulted in both blockade of the OX40-OX40L receptor-ligand interaction and depletion of OX40L-positive cells. The use of a blocking, OX40L-specific mAb thus presents a promising strategy for the treatment of allergic diseases associated with pathologic Th2 immune responses.

AB - Thymic stromal lymphopoietin (TSLP) potently induces deregulation of Th2 responses, a hallmark feature of allergic inflammatory diseases such as asthma, atopic dermatitis, and allergic rhinitis. However, direct downstream in vivo mediators in the TSLP-induced atopic immune cascade have not been identified. In our current study, we have shown that OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. Treating mice with OX40L-blocking antibodies substantially inhibited immune responses induced by TSLP in the lung and skin, including Th2 inflammatory cell infiltration, cytokine secretion, and IgE production. OX40L-blocking antibodies also inhibited antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. This treatment resulted in both blockade of the OX40-OX40L receptor-ligand interaction and depletion of OX40L-positive cells. The use of a blocking, OX40L-specific mAb thus presents a promising strategy for the treatment of allergic diseases associated with pathologic Th2 immune responses.

UR - http://www.scopus.com/inward/record.url?scp=36849060458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849060458&partnerID=8YFLogxK

U2 - 10.1172/JCI33559

DO - 10.1172/JCI33559

M3 - Article

VL - 117

SP - 3868

EP - 3878

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -